BEYOND: a randomized, double blind, placebo controlled, multicenter, phase III study of first line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with …
Journal of Clinical Oncology(2015)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要